Abstract:Abstract The Hippo signaling cascade is a major pathway that integrates a broad spectrum of mechanosensory signals at the plasma membrane and regulates response via control of cell proliferation, self-renewal, differentiation, and apoptosis. Dysregulation of this pathway has been observed across a range of cancer types and results in an altered activity of its primary downstream effectors, the oncogenic transcription factors YAP/TAZ. For example, both germline and somatic loss-of-function mutations in the tumor suppressor gene NF2, a component of Hippo, induce hyperactivation of YAP/TAZ, transcriptional changes and ultimately result in tumor growth. The Hippo signaling pathway is an attractive target for drug discovery efforts, however, it is highly complex and still incompletely understood. Hence it is indispensable to get a deeper insight into the Hippo - YAP/TAZ signaling axis. To this end, we performed a genome-wide CRISPR knockout screen in the triple-negative breast cancer (TNBC) cell line MDA-MB231 (NF2LOF) expressing a YAP/TAZ reporter construct. We identified both negative and positive regulators of YAP/TAZ in breast cancer cells. In a second step, screening hits were further characterized in a focused single-cell CRISPR screen (Perturb-Seq), aiming at better understanding of the effects on YAP/TAZ activity regulation and downstream effects on gene expression. Here we present the technical details of our screening approaches and the results of perturbing known and novel regulators of YAP/TAZ on single cell level. We discuss the use of Perturb-Seq in the initial validation of hits from genome-wide screens and provide data that may serve as a basis for future drug discovery efforts, seeking for novel and effective treatments for triple-negative breast cancers and other malignancies with Hippo pathway alterations. Citation Format: Mareike Berlak, Zuzanna Makowska, Filippos Klironomos, Julia Kuehnlenz, Atanas Kamburov, Andreas Steffen, Martin Lange, Barbara Nicke, Ralf Lesche, Peter Staller, Charlotte Kopitz, Jan Naujoks. Identification of novel YAP/TAZ pathway regulators in the triple-negative breast cancer cell line MDA-MB231 using single-cell CRISPR screening [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6089.

Multiplexed screening reveals how cancer-specific alternative polyadenylation shapes tumor growth in vivo

Abstract 6089: Identification of novel YAP/TAZ pathway regulators in the triple-negative breast cancer cell line MDA-MB231 using single-cell CRISPR screening

Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma

Genome-wide Profiling of Polyadenylation Sites Reveals a Link Between Selective Polyadenylation and Cancer Metastasis

Alternative Polyadenylation Modification Patterns Reveal Essential Posttranscription Regulatory Mechanisms of Tumorigenesis in Multiple Tumor Types.

APC mutations dysregulate alternative polyadenylation in cancer

The Transcriptional Landscape of Immune-Response 3′-UTR Alternative Polyadenylation in Melanoma

Large-scale alternative polyadenylation-wide association studies to identify putative cancer susceptibility genes

Dichotomous intronic polyadenylation profiles reveal multifaceted gene functions in the pan-cancer transcriptome

Alternative polyadenylation shapes the molecular and clinical features of lung adenocarcinoma

A Cancer-Specific Ubiquitin Ligase Drives Mrna Alternative Polyadenylation by Ubiquitinating the Mrna 3' End Processing Complex.

Data from Characterization of Immune-Related Alternative Polyadenylation Events in Cancer Immunotherapy

Alternative polyadenylation of single cells delineates cell types and serves as a prognostic marker in early stage breast cancer

Alternative Polyadenylation of Mrna and Its Role in Cancer

Alternative Polyadenylation in Glioblastoma Multiforme and Changes in Predicted RNA Binding Protein Profiles.

Large-scale alternative polyadenylation (APA)-wide association studies to identify putative susceptibility genes in human common cancers

Genetic variants that impact alternative polyadenylation in cancer represent candidate causal risk loci

Cell Cycle Regulation by Alternative Polyadenylation of CCND1.

Alternative Polyadenylation: Methods, Mechanism, Function, and Role in Cancer.

Characterization of immune-related alternative polyadenylation events in cancer immunotherapy

Cell-type-specific alternative polyadenylation promotes oncogenic gene expression in non-small cell lung cancer progression